Drug Disposition in Cystic Fibrosis

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.35, Iss.4, 1998-10, pp. : 313-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging drug treatments for cystic fibrosis

By Zeitlin Pamela L

Expert Opinion on Emerging Drugs, Vol. 12, Iss. 2, 2007-05 ,pp. : 329-336

Informa Healthcare

Access to resources Recommend Favorite

Emerging drug treatments for cystic fibrosis

By Zeitlin Pamela L

Expert Opinion on Emerging Drugs, Vol. 8, Iss. 2, 2003-11 ,pp. : 523-535

Informa Healthcare

Access to resources Recommend Favorite

Cystic Fibrosis Transmembrane Conductance Regulator Modulators for Personalized Drug Treatment of Cystic Fibrosis: Progress to Date

By Becq Frédéric

Drugs, Vol. 70, Iss. 3, 2010-02 ,pp. : 241-259

Adis International

Access to resources Recommend Favorite

Cystic Fibrosis and the Use of Pharmacogenomics to Determine Surrogate Endpoints for Drug Discovery

By Eidelman O. Zhang J. Srivastava M. Pollard H.B.

American Journal of PharmacoGenomics, Vol. 1, Iss. 3, 2001-01 ,pp. : 223-238

Adis International

Access to resources Recommend Favorite

Liver and Pancreatic Disease in Cystic Fibrosis: Clinics and Drug Therapy

Clinical Immunology, Endocrine & Metabolic Drugs, Vol. 3, Iss. 2, 2017-08 ,pp. : 117-129

Bentham Science Publishers

Access to resources Recommend Favorite